Hui Tao1,2, Jing-Jing Yang3, Kai-Hu Shi1,2, Jun Li4. 1. Department of Cardiothoracic Surgery, The Second Hospital of Anhui Medical University, Hefei, 230601, China. 2. Cardiovascular Research Center, Anhui Medical University, Hefei, 230601, China. 3. Department of Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China. yjjncs01@126.com. 4. School of Pharmacy, Anhui Medical University, Mei Shan Road, Hefei, Anhui, 230032, China. yncs01@hotmail.com.
Abstract
AIM AND OBJECTIVE: Cardiac fibrosis is an important pathological feature of cardiac remodeling in heart diseases. Methyl-CpG-binding protein 2 (MeCP2) is a transcription inhibitor, and plays a key role in the fibrotic diseases. However, the precise role of MeCP2 in cardiac fibrosis remains unclear. α-tubulin plays an essential role in cell function, whereby the acetylation state of α-Tubulin dictates the efficiency of cell proliferation and differentiation. This study was undertaken to investigate that MeCP2 dynamics affect the acetylation state of α-tubulin in the cardiac fibrosis. METHODS: Forty adult male Sprague-Dawley (SD) rats were randomly divided into two groups, cardiac fibrosis was produced by common ISO. Cardiac fibroblasts (CFs) were harvested from SD neonate rats and cultured. The expression of HDAC6, MeCP2, α-SMA, collagen I was measured by western blotting and qRT-PCR. siRNA of HDAC6 and MeCP2 effect the proliferation of cardiac fibroblasts, and affect the acetylation state of α-tubulin. RESULTS: We have found the acetylation state of α-tubulin in cardiac fibroblasts as well as cardiac tissue from a ISO-induced rat cardiac fibrosis model and observed a reduction in acetylated α-tubulin and an increase in the α-tubulin-specific deacetylase, histone deacetylase 6 (HDAC6). Furthermore, we have shown that treatment of cardiac fibroblasts with HDAC6 inhibitor Tubastatin A and HDAC6-siRNA can restore α-tubulin acetylation levels. In addition, treatment of cardiac fibroblasts with MeCP2-siRNA blocked cell proliferation. Knockdown of MeCP2 suppresses HDAC6 expression in activated cardiac fibroblasts but increases the acetylation of α-tubulin. CONCLUSIONS: We demonstrated that MeCP2 may negatively control the acetylation of α-tubulin through HDAC6 in cardiac fibroblast proliferation and fibrosis. This study indicated that MeCP2 could be a potentially new therapeutic option for cardiac fibrosis.
AIM AND OBJECTIVE:Cardiac fibrosis is an important pathological feature of cardiac remodeling in heart diseases. Methyl-CpG-binding protein 2 (MeCP2) is a transcription inhibitor, and plays a key role in the fibrotic diseases. However, the precise role of MeCP2 in cardiac fibrosis remains unclear. α-tubulin plays an essential role in cell function, whereby the acetylation state of α-Tubulin dictates the efficiency of cell proliferation and differentiation. This study was undertaken to investigate that MeCP2 dynamics affect the acetylation state of α-tubulin in the cardiac fibrosis. METHODS: Forty adult male Sprague-Dawley (SD) rats were randomly divided into two groups, cardiac fibrosis was produced by common ISO. Cardiac fibroblasts (CFs) were harvested from SD neonate rats and cultured. The expression of HDAC6, MeCP2, α-SMA, collagen I was measured by western blotting and qRT-PCR. siRNA of HDAC6 and MeCP2 effect the proliferation of cardiac fibroblasts, and affect the acetylation state of α-tubulin. RESULTS: We have found the acetylation state of α-tubulin in cardiac fibroblasts as well as cardiac tissue from a ISO-induced ratcardiac fibrosis model and observed a reduction in acetylated α-tubulin and an increase in the α-tubulin-specific deacetylase, histone deacetylase 6 (HDAC6). Furthermore, we have shown that treatment of cardiac fibroblasts with HDAC6 inhibitor Tubastatin A and HDAC6-siRNA can restore α-tubulin acetylation levels. In addition, treatment of cardiac fibroblasts with MeCP2-siRNA blocked cell proliferation. Knockdown of MeCP2 suppresses HDAC6 expression in activated cardiac fibroblasts but increases the acetylation of α-tubulin. CONCLUSIONS: We demonstrated that MeCP2 may negatively control the acetylation of α-tubulin through HDAC6 in cardiac fibroblast proliferation and fibrosis. This study indicated that MeCP2 could be a potentially new therapeutic option for cardiac fibrosis.
Entities:
Keywords:
Cardiac fibroblasts; Histone deacetylase 6; Methyl-CpG-binding protein 2
Authors: Hae Jin Kee; Eun Hui Bae; Sangha Park; Ko Eun Lee; Sang Heon Suh; Soo Wan Kim; Myung Ho Jeong Journal: Kidney Blood Press Res Date: 2013-07-08 Impact factor: 2.687
Authors: Lei Wu; SuFey Ong; Monica V Talor; Jobert G Barin; G Christian Baldeviano; David A Kass; Djahida Bedja; Hao Zhang; Asfandyar Sheikh; Joseph B Margolick; Yoichiro Iwakura; Noel R Rose; Daniela Ciháková Journal: J Exp Med Date: 2014-06-16 Impact factor: 14.307
Authors: Yan Leng; Yang Wu; Shaoqing Lei; Bin Zhou; Zhen Qiu; Kai Wang; Zhongyuan Xia Journal: Oxid Med Cell Longev Date: 2018-06-25 Impact factor: 6.543